World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
107
Citations
55287
World Ranking
6137
National Ranking
235

Edo Vellenga publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Edo Vellenga sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 625 publications — 74th percentile

74% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Edo Vellenga D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Edo Vellenga sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 107 D-Index — 70th percentile

70% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Edo Vellenga is affiliated with the University Medical Center Groningen in the Netherlands. Their research focuses predominantly within the fields of Medicine and Biochemistry, Genetics and Molecular Biology, with a specialized emphasis on Hematology, Genetics, Molecular Biology, Oncology, and Physiology.

The scientist's main topics of work include:

  • Acute Myeloid Leukemia Research
  • Multiple Myeloma Research and Treatments
  • Blood disorders and treatments
  • Telomeres, Telomerase, and Senescence
  • Hematopoietic Stem Cell Transplantation
  • Acute Lymphoblastic Leukemia research
  • Myeloproliferative Neoplasms: Diagnosis and Treatment

Among the recent publications by Edo Vellenga are:

  • Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes, 2020, New England Journal of Medicine
  • Imetelstat Achieves Meaningful and Durable Transfusion Independence in High Transfusion-Burden Patients With Lower-Risk Myelodysplastic Syndromes in a Phase II Study, 2020, Journal of Clinical Oncology
  • Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial, 2021, Blood Advances
  • The IL1-IL1RAP axis plays an important role in the inflammatory leukemic niche that favors acute myeloid leukemia proliferation over normal hematopoiesis, 2020, Haematologica
  • Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS, 2020, Leukemia

Frequent publication venues where Edo Vellenga's work appears include:

  • Blood Advances
  • Leukemia
  • Blood
  • Experimental Hematology
  • New England Journal of Medicine

Frequent collaborators in their research include:

  • Gerwin Huls
  • Walter J. F. M. van der Velden
  • Okke de Weerdt
  • Saskia K. Klein
  • Bob Löwenberg

Best Publications

  • Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)

    Daniel J. Klionsky;Amal Kamal Abdel-Aziz;Sara Abdelfatah;Mahmoud Abdellatif

  • Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

    Daniel J. Klionsky;Kotb Abdelmohsen;Akihisa Abe;Joynal Abedin

  • Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 Trial

    Pieter Sonneveld;Ingo G.H. Schmidt-Wolf;Bronno Van Der Holt;Laila El Jarari

  • High-dose daunorubicin in older patients with acute myeloid leukemia.

    Bob Löwenberg;Gert J. Ossenkoppele;Wim van Putten;Harry C. Schouten

  • Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)

    Hagop M. Kantarjian;Neil P. Shah;Jorge E. Cortes;Michele Baccarani

  • Prognostic Index for Adult Patients With Acute Myeloid Leukemia in First Relapse

    Dimitri A. Breems;Wim L.J. Van Putten;Peter C. Huijgens;Gert J. Ossenkoppele

  • Cytarabine dose for acute myeloid leukemia.

    Bob Lowenberg;Thomas Pabst;Edo Vellenga;Wim van Putten

  • Uncovering regulatory pathways that affect hematopoietic stem cell function using 'genetical genomics'.

    Leonid Bystrykh;Ellen Weersing;Bert Dontje;Sue Sutton

  • The possible role of matrix metalloproteinase (MMP)-2 and MMP-9 in cancer, e.g. acute leukemia

    G. Klein;Edo Vellenga;Marco Fraaije;Willem Kamps

  • Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes

    Pierre Fenaux;Pierre Fenaux;Uwe Platzbecker;Ghulam J. Mufti;Guillermo Garcia-Manero

  • Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin.

    Javier de Serna;Pau Montesinos;Edo Vellenga;Chelo Rayón

  • Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors

    Pau Montesinos;Juan M. Bergua;Edo Vellenga;Chelo Rayón

  • Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients

    Annemiek Broyl;Dirk Hose;Henk Lokhorst;Yvonne de Knegt

  • A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma

    Henk M. Lokhorst;Bronno van der Holt;Sonja Zweegman;Edo Vellenga

  • Ultrastructural study shows morphologic features of apoptosis and para-apoptosis in megakaryocytes from patients with idiopathic thrombocytopenic purpura

    Ewout J. Houwerzijl;Nel R. Blom;Johannes J. L. van der Want;Mariet T. Esselink

  • BLUEPRINT to decode the epigenetic signature written in blood

    David Adams;Lucia Altucci;Stylionos E. Antonarakis;Juan Ballesteros

  • Clinical, Molecular, and Prognostic Significance of WHO Type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and Various Other 3q Abnormalities in Acute Myeloid Leukemia

    Sanne Lugthart;Stefan Gröschel;H. Berna Beverloo;Sabine Kayser

  • Effects of recombinant human interleukin-6 in cancer patients: a phase I-II study

    M. M. Van Gameren;P. H. B. Willemse;N. H. Mulder;P. C. Limburg

  • Erratum to: Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) (Autophagy, 12, 1, 1-222, 10.1080/15548627.2015.1100356

    Daniel J. Klionsky;Kotb Abdelmohsen;Akihisa Abe;Joynal Abedin

  • Tissue distribution of the death ligand TRAIL and its receptors

    Diana C. Spierings;Elisabeth G. de Vries;Edo Vellenga;Fiona A. van den Heuvel

Frequent Co-Authors

Jan Jacob Schuringa
Jan Jacob Schuringa University Medical Center Groningen
Bob Löwenberg
Bob Löwenberg Erasmus MC
Pieter Sonneveld
Pieter Sonneveld Erasmus University Rotterdam
Sonja Zweegman
Sonja Zweegman Amsterdam UMC
Joost H.A. Martens
Joost H.A. Martens Radboud University
Miguel A. Sanz
Miguel A. Sanz University of Valencia
Elisabeth G.E. de Vries
Elisabeth G.E. de Vries University Medical Center Groningen
Gerald de Haan
Gerald de Haan University Medical Center Groningen

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re exploring options beyond a traditional MD program, several online degrees and healthcare careers offer flexible entry points and valuable opportunities. Medical billing and coding is a fast-growing field where students can start with medical billing and coding online courses cost far less than many in-person alternatives. These programs often allow you to begin working in healthcare administration within a year.

Nursing remains a versatile career path—online study options include everything from entry-level RN to advanced practitioner. Curious about how much it costs? Learn more about how much is online nursing school and find affordable programs tailored to your goals.

For registered nurses aiming to advance, the cheapest online np programs make becoming a Nurse Practitioner accessible and budget-friendly. Likewise, ambitious nurses can earn a doctorate through the cheapest dnp programs online, opening doors to teaching, leadership, and research.

Each of these pathways provides distinct advantages in terms of flexibility, career security, and cost. Online education in healthcare continues to expand, making it easier to enter or advance in the medical field from anywhere.

Best Scientists Citing Edo Vellenga

Trending Scientists

Recently Published Articles